Safety Evaluation of Tarlatamab in SCLC: A Systematic Review and Meta-Analysis

Elsa Vitale, Lorenza Maistrello, Alessandro Rizzo, Domenico Galetta, Vito Longo · 2026

Read Safety Evaluation of Tarlatamab in SCLC: A Systematic Review and Meta-Analysis by Elsa Vitale, Lorenza Maistrello, Alessandro Rizzo, Domenico Galetta, Vito Longo (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13524861.txt.

Description

A new immune drug for small cell lung cancer, tarlatamab, helps T cells attack tumor cells but brings its own pattern of side effects. Elsa Vitale and co-authors pooled the safety results of the early trials in 2026. Four studies with 457 patients fed their combined analysis of treatment-related harms.

Severe side effects were common, affecting about two in five patients, and a similar share had serious events. A fever-and-inflammation reaction called cytokine release syndrome occurred in over half the patients, while appetite loss, fever, and altered taste each hit about a third. Few patients stopped treatment for side effects. The authors call for research on who is at risk and how to prevent the worst reactions.

Catalog record

CREATORElsa Vitale, Lorenza Maistrello, Alessandro Rizzo, Domenico Galetta, Vito Longo
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE25 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13524861

Browse the full library · About the Tower of Babel